Recent insights into the Smith-Lemli-Opitz syndrome

Area of Science:

• Biochemistry
• Genetics
• Developmental Biology

Background:

• Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder characterized by multiple congenital anomalies and intellectual disability.
• It stems from an inborn error in post-squalene cholesterol biosynthesis, specifically mutations in the 3beta-hydroxysterol-Delta7 reductase gene (DHCR7).
• DHCR7 deficiency disrupts cholesterol and desmosterol production, leading to elevated 7-dehydrocholesterol (7DHC) and developmental abnormalities.

Purpose of the Study:

• To review recent advancements in understanding the genetics of SLOS.
• To elucidate the pathophysiology of SLOS, focusing on cholesterol biosynthesis defects.
• To summarize current and potential therapeutic strategies for SLOS treatment.

Main Methods:

• Review of genetic mutations identified in SLOS patients.
• Analysis of data from two genetic mouse models mimicking SLOS developmental abnormalities.
• Synthesis of current research on SLOS pathophysiology and treatment.

Main Results:

• Over 121 distinct DHCR7 mutations identified in more than 250 SLOS patients, exhibiting a spectrum of clinical severity.
• Genetic mouse models have successfully replicated key developmental issues seen in SLOS, aiding in pathogenesis studies.
• Insights into the critical role of the cholesterol biosynthesis pathway in human development.

Conclusions:

• DHCR7 mutations are the cause of SLOS, impacting cholesterol synthesis and leading to significant developmental challenges.
• Understanding SLOS genetics and pathophysiology is crucial for developing effective treatments.
• Ongoing research focuses on novel therapeutic approaches to manage SLOS.